Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,354 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Health-Related Quality of Life and Side Effects in Gastrointestinal Stromal Tumor (GIST) Patients Treated with Tyrosine Kinase Inhibitors: A Systematic Review of the Literature.
van de Wal D, Elie M, Le Cesne A, Fumagalli E, den Hollander D, Jones RL, Marquina G, Steeghs N, van der Graaf WTA, Husson O. van de Wal D, et al. Among authors: jones rl. Cancers (Basel). 2022 Apr 5;14(7):1832. doi: 10.3390/cancers14071832. Cancers (Basel). 2022. PMID: 35406604 Free PMC article. Review.
Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study.
Grosso F, Jones RL, Demetri GD, Judson IR, Blay JY, Le Cesne A, Sanfilippo R, Casieri P, Collini P, Dileo P, Spreafico C, Stacchiotti S, Tamborini E, Tercero JC, Jimeno J, D'Incalci M, Gronchi A, Fletcher JA, Pilotti S, Casali PG. Grosso F, et al. Among authors: jones rl. Lancet Oncol. 2007 Jul;8(7):595-602. doi: 10.1016/S1470-2045(07)70175-4. Lancet Oncol. 2007. PMID: 17586092
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.
Demetri GD, Reichardt P, Kang YK, Blay JY, Rutkowski P, Gelderblom H, Hohenberger P, Leahy M, von Mehren M, Joensuu H, Badalamenti G, Blackstein M, Le Cesne A, Schöffski P, Maki RG, Bauer S, Nguyen BB, Xu J, Nishida T, Chung J, Kappeler C, Kuss I, Laurent D, Casali PG; GRID study investigators. Demetri GD, et al. Lancet. 2013 Jan 26;381(9863):295-302. doi: 10.1016/S0140-6736(12)61857-1. Epub 2012 Nov 22. Lancet. 2013. PMID: 23177515 Free PMC article. Clinical Trial.
Redefining the standard of care in metastatic leiomyosarcoma.
Noujaim J, van der Graaf WT, Jones RL. Noujaim J, et al. Among authors: jones rl. Lancet Oncol. 2015 Apr;16(4):360-2. doi: 10.1016/S1470-2045(15)70107-5. Epub 2015 Mar 18. Lancet Oncol. 2015. PMID: 25795407 No abstract available.
Current status and unanswered questions on the use of Denosumab in giant cell tumor of bone.
Gaston CL, Grimer RJ, Parry M, Stacchiotti S, Dei Tos AP, Gelderblom H, Ferrari S, Baldi GG, Jones RL, Chawla S, Casali P, LeCesne A, Blay JY, Dijkstra SP, Thomas DM, Rutkowski P. Gaston CL, et al. Among authors: jones rl. Clin Sarcoma Res. 2016 Sep 14;6(1):15. doi: 10.1186/s13569-016-0056-0. eCollection 2016. Clin Sarcoma Res. 2016. PMID: 27651889 Free PMC article. Review.
Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis.
Kollár A, Jones RL, Stacchiotti S, Gelderblom H, Guida M, Grignani G, Steeghs N, Safwat A, Katz D, Duffaud F, Sleijfer S, van der Graaf WT, Touati N, Litière S, Marreaud S, Gronchi A, Kasper B. Kollár A, et al. Among authors: jones rl. Acta Oncol. 2017 Jan;56(1):88-92. doi: 10.1080/0284186X.2016.1234068. Epub 2016 Nov 14. Acta Oncol. 2017. PMID: 27838944 Clinical Trial.
1,354 results